Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Other Non Operating Income (2023 - 2025)

NewAmsterdam Pharma's Other Non Operating Income history spans 3 years, with the latest figure at -$23.7 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 220.85% year-over-year to -$23.7 million; the TTM value through Dec 2025 reached $13.1 million, down 72.75%, while the annual FY2025 figure was $13.1 million, 66.16% down from the prior year.
  • Other Non Operating Income for Q4 2025 was -$23.7 million at NewAmsterdam Pharma, down from $23.8 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $30.2 million in Q1 2024 and bottomed at -$23.7 million in Q4 2025.
  • The 3-year median for Other Non Operating Income is $3.9 million (2023), against an average of $5.5 million.
  • The largest YoY upside for Other Non Operating Income was 886.24% in 2024 against a maximum downside of 9061.11% in 2024.
  • A 3-year view of Other Non Operating Income shows it stood at $5.2 million in 2023, then soared by 275.14% to $19.6 million in 2024, then plummeted by 220.85% to -$23.7 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Other Non Operating Income are -$23.7 million (Q4 2025), $23.8 million (Q3 2025), and $26.7 million (Q2 2025).